NCT05018260

Brief Summary

The purpose of this study is to compare the clinical efficacy of treatment using gaze contingent music reward therapy (GC-MRT) with attention control treatment based on a similar paradigm, for social anxiety disorder (SAD)

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started May 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2021

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

August 18, 2021

Completed
6 days until next milestone

First Posted

Study publicly available on registry

August 24, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2022

Completed
Last Updated

January 4, 2023

Status Verified

January 1, 2023

Enrollment Period

8 months

First QC Date

August 18, 2021

Last Update Submit

January 1, 2023

Conditions

Keywords

social anxietysocial phobiaattention bias modificationattention control

Outcome Measures

Primary Outcomes (1)

  • Change from baseline - the Liebowitz Social Anxiety Scale (LSAS) - Diagnostic Interview scores

    The Liebowitz Social Anxiety Scale (LSAS) is a 24-item scale, each item corresponding to a situation selected on the basis of clinical experience. Each item is rated on a severity scale ranging from 0 to 3 with regard to the passing week, measuring separately two components of social anxiety, specifically, fear/anxiety and avoidance of social interaction and performance situations. The minimum and maximum values of the LSAS total score are 0 and 144, respectively, with higher scores mean worse outcome. Although the assessor may request and ask for further detail and adjust the rating based on clinical experience, this option is not often exercised, and inter-rater agreement is not considered to be a relevant concern.

    at baseline, one week after end of intervention

Secondary Outcomes (2)

  • Change from baseline - the Social Phobia Inventory scores

    at baseline, one week after end of intervention

  • Clinical Global Impression

    at baseline, one week after end of intervention

Other Outcomes (4)

  • Change from baseline -Attention Control Scale- ACS

    at baseline, one week after end of intervention

  • Change from baseline - Patient Health Questionnaire- PHQ9

    at baseline, one week after end of intervention

  • Viewing patterns on disgusted and neutral faces, and round/sharp shapes< representing attention bias.

    at baseline, one week after end of intervention

  • +1 more other outcomes

Study Arms (2)

GCMRT

EXPERIMENTAL

Attention bias modification: participants will receive gaze-contingent feedback according to their viewing patterns on disgusted and neutral faces

Behavioral: Attention Bias Modification

attention control

EXPERIMENTAL

Attention control modification: participants will receive gaze-contingent feedback according to their viewing patterns on rounded and sharp geometric shapes

Behavioral: Attention Control

Interventions

Feedback according to participants' viewing patterns, in order to modify their attention bias to threat

GCMRT

Feedback according to participants' viewing patterns, in order to strengthen their attention control

attention control

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • A signed consent form
  • Men and women between the ages of 18 and 65.
  • Meeting a current diagnosis of Social Anxiety Disorder (SP) according to the DSM-IV.
  • SP as the primary diagnosis: In cases of co-morbidity, SP will be deemed as the most distressing and clinically significant condition among the co-morbid disorders.
  • No current pharmaco-therapy.

You may not qualify if:

  • A diagnosis of psychotic or bipolar disorders.
  • A diagnosis of a neurological disorder (i.e., epilepsy, brain injury).
  • Drug or alcohol abuse.
  • Any current pharmacological treatment.
  • Any current psychotherapeutic treatment.
  • Change in treatment during the study.
  • Poor judgment capacity (i.e., children under 18 and special populations).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tel Aviv University

Tel Aviv, 55555, Israel

Location

MeSH Terms

Conditions

Phobia, Social

Condition Hierarchy (Ancestors)

Phobic DisordersAnxiety DisordersMental Disorders

Study Officials

  • Yair Bar-Haim, PhD

    Tel Aviv University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
particiapants, investigators and outcome assessors are blind to allocation
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor

Study Record Dates

First Submitted

August 18, 2021

First Posted

August 24, 2021

Study Start

May 1, 2021

Primary Completion

January 1, 2022

Study Completion

April 1, 2022

Last Updated

January 4, 2023

Record last verified: 2023-01

Data Sharing

IPD Sharing
Will not share

Locations